AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 181 min read$MCK

TYLER BRIAN S. sold $6.6M of MCK

TYLER BRIAN S. (Chief Executive Officer) sold 8,463 shares of MCKESSON CORP (MCK) at $775.13 ($6.56M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TYLER BRIAN S.
Published Jun 18, 2026, 7:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The CEO executed an open-market sale of 8,463 shares at $775.13/share; the plan is pre-arranged under Rule 10b5-1.

02

Market read

This provides a fresh datapoint on insider activity but lacks any new fundamental or regulatory catalyst.

03

What to watch

Traders should compare with prior insider transactions and the CEO’s total holdings trend; a single sale often has limited interpretive power.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-06-18 (sale dated 2026-06-17)

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson CEO Tyler Brian S. filed an open-market sale of 8,463 shares at $775.13 on 2026-06-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely short-lived.

Evidence & confidence

The filing is a pre-arranged 10b5-1 plan and the article provides no accompanying operational or guidance change.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification/tax needs and may not reflect bearish expectations, especially under a 10b5-1 plan.

Key entities

  • equity issuer
    MCK

    McKesson Corp, the issuer of the Form 4 insider transaction.

  • insider
    Tyler Brian S.

    Chief Executive Officer and director who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

finance.yahoo.com6 min
AUG 6
$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

news.alphastreet.com2 min
AUG 5
$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.

finance.biggo.com4 min